Frontlight ResearchEarly access
CompletedPhase 2
NAPO - Novel Approach for Oligospermia
Key facts
- Who runs it
- Herlev Hospital
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 60 people enrolled
- Started
- 1 Apr 2024
- Ended
- 27 Jan 2025
- Type of study
- Interventional
- Record updated
- 19 December 2023
Who can take part
- Age
- 18 years to 64 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Infertile men >18 years and <60 years of age with reduced sperm production (Sperm concentration <2 mio/mL) - Serum AMH > 30 pmol/L
Who cannot take part
- Poor dental status og dental implants
- Men with chronic diseases (diabetes mellitus, thyroid disease, endocrine diseases requirering treatment such as sarcoidosis, tuberculosis, wegeners, vasculitis as well as inflammatory bowel diseases e.g. chron's disease or ulcerative colitis etc)
- Latex allergy
- Men with active or previous malignant disease
- Serum FSH <3 IU/L
- Serum ionized calcium < 1,18 mmol/L, Total calcium < 2.14 mmol/L or Albumin corrected calcium <2.17 mmol/L
- Serum 25OHD < 25 nmol/L
- eGFR <60 mL/min/1.73m^2
- Any case with indication for testis biopsy
- BMI >35 kg/m^2
- Sperm cell concentration <0.01 mio/mL
- Men in treatment for osteoporosis
- Men with obstructive oligospermia (Sperm volume <0.9 mL) or who has been vasectomized
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this intervention is to investigate whether Denosumab can improve semen quality in a subgroup of infertile men.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 19 December 2023